A recent report released by the private insurance company GreenShield has revealed that drug costs in Canada saw a significant increase of 9.5 per cent in 2025 compared to the previous year. This rise in costs is attributed primarily to the expenses related to GLP-1 medications, which are often prescribed for weight management, and various treatments for Attention Deficit Hyperactivity Disorder (ADHD).
The report underscores the ongoing challenges faced by the Canadian healthcare system regarding prescription drug pricing and insurance coverage. With the escalating costs of prescriptions, more Canadians are likely to rely on their insurance to cover these expenses, leading to an increase in drug insurance claims.
As part of the broader conversation around healthcare costs and access to medication in Canada, the findings from GreenShield may influence future discussions about how drug therapies are covered under insurance plans. Stakeholders in the healthcare and insurance industries are expected to examine these trends closely as they impact policy decisions and consumer access to essential medications.
Analyzed Canadian Outlets (1)
1 headline